GLP-1 Supply + Dual Oral Peptide Wins Set Up FY27 Revenue Inflection

Enlicitide and icotrokinra contributions expected from CY2027 alongside GLP-1 molecule supply ramp in FY27, creating converging tailwinds for CDMO/API players with oral peptide manufacturing scale.

ndtv-profit-business · 7/15/2026, 4:02:28 AM · Ask about this →